mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

The effects of doxycycline on reducing symptoms in knee osteoarthritis: Results from a triple-blinded randomised controlled trial

Snijders GF et al. – Doxycycline is not effective in reducing symptoms in knee osteoarthritis patients over a 24-week study period, but is associated with an increased risk of adverse events. Although a possible structure-modifying effect of doxycycline was previously suggested, this is not accompanied by symptom relief in the short and medium term.

Methods

  • A 24-week, randomised, triple-blind, placebo controlled trial
  • Assessed symptomatic effectiveness of doxycycline twice a day 100 mg in knee OA patients according to clinical and radiological American College of Rheumatology classification criteria
  • Primary endpoint was difference in proportion of participants in both study groups achieving clinical response defined by OMERACT–OARSI set of responder criteria
  • Secondary endpoints included pain, stiffness, daily functioning, patient global assessment,QOL, OA-related medication and SE

Results
  • 232 patients
  • Randomly assigned
  • At study end, 31% of participants met primary endpoint in both groups
  • Except for more AE in doxycycline group, no differences on secondary endpoints
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close